Effect of Low-dose Aspirin for Stomach Cancer Prevention After Endoscopic Resection of Gastric Neoplasm (EASTERN): a Randomized Controlled Trial

Who is this study for? Patients with early gastric cancer with negative H. pylori status who underwent endoscopic submucosal dissection
What treatments are being studied? Aspirin
Status: Recruiting
Location: See all (10) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

This study aimed to investigate the effect of low-dose (100 mg) asprin on the prevention of gastric cancer in the early gastric cancer patients with negative H. pylori status who underwent endoscopic submucosal dissection.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Maximum Age: 70
Healthy Volunteers: f
View:

• Men and women aged 19-70 years who underwent endoscopic resection for high-grade adenoma or early gastric cancer (category 4 \[non-invasive high grade neoplasm\] or category 5 \[invasive neoplasia\] according to the Vienna classification of gastrointestinal epithelial neoplasia \[Schlemper RJ, et al. Gut 2000;47:251-255.\])

• Final pathological results after endoscopic resection met the absolute or expanded criteria according to the Japanese Gastric Cancer Treatment guideline 2014 (version 4)

• Patients who had negative H. pylori status or those who eradicated H. pylori status

• Willingness to sign an informed consent form

Locations
Other Locations
Republic of Korea
Kosin University Gospel Hospital
RECRUITING
Busan
Pusan National University Hospital
RECRUITING
Busan
Hallym University Chuncheon Sacred Heart Hospital
RECRUITING
Chuncheon
Kyungpook National University Chilgok Hospital
RECRUITING
Daegu
National Cancer Center
RECRUITING
Goyang
Chonnam National University Hospital
RECRUITING
Gwangju
Incheon St.Mary's Hospital/The Catholic University
RECRUITING
Incheon
Asan Medical Center
NOT_YET_RECRUITING
Seoul
Chung-Ang University Hospital
RECRUITING
Seoul
SMG-SNU Boramae Medical Center
RECRUITING
Seoul
Contact Information
Primary
Il Ju Choi, M.D., Ph.D.
cij1224@ncc.re.kr
+82-31-920-2282
Backup
Young-Il Kim, MD
11996@ncc.re.kr
+82-31-920-1712
Time Frame
Start Date: 2020-02-15
Estimated Completion Date: 2032-03-31
Participants
Target number of participants: 1700
Treatments
Active_comparator: Aspirin
Enteric coated aspirin
Placebo_comparator: Placebo
Enteric coated aspirin placebo
Related Therapeutic Areas
Sponsors
Collaborators: Seoul National University Bundang Hospital, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, Samsung Medical Center, Asan Medical Center, SMG-SNU Boramae Medical Center, Chonnam National University Hospital, Kosin University Gospel Hospital, Incheon St.Mary's Hospital/The Catholic University, Chilgok Kyungpook National University, Severance Hospital, Pusan National University Hospital, Hallym University Medical Center
Leads: National Cancer Center, Korea

This content was sourced from clinicaltrials.gov